David A Hildeman
NIH Rank #1558
- R01 Award PI
- Top 10% by Linked Awards
- Multiple Award Orgs
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 7618483Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2025 award categories
- Pathology
- CHEMISTRY
NIH Funding · FY2025
Linked Award Amount
$4.7M
Full award amounts, FY2025
Award Records
3
Records listing this PI
Award-Linked Rank
#1,558
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing David A Hildeman as a PI. Multi-PI records show the full award amount for context.
- $3.8Maward amount
- 1R21AI191060-01R21Bringing alloreactivity into focus with the lens of TCR cross-reactivity$459.4Kaward amount
- 1R21AI190579-01R21Cell specific roles of CD153 and CD30 in regulation of immune responses$441.4Kaward amount
Award organizations
Organizations that administered FY2025 awards listing David A Hildeman as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024ScienceDex Coverage BeginsEarliest loaded PI award records: FY2024
- 2024$500K Cumulative Linked Award Amount
- 2024R01 Award Record
- 2025$1M Cumulative Linked Award Amount
- 2025$2M Cumulative Linked Award Amount
- 2025$5M Cumulative Linked Award Amount
- 2025Reached Top 50% by Award-Linked RankRanked #1558
- 2025Reached Top 25% by Award-Linked RankRanked #1558
- 2025Reached Top 10% by Award-Linked RankRanked #1558
- 2025Multiple Award OrganizationsAwards administered by 3 organizations
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as David A Hildeman.